Through Springtide Ventures we co-finance the research and development of the medicinal substance MitoTam being carried out by the Czech Academy of Sciences
Results obtained so far show effectiveness in oncological and senolytical applications
Clinical trials of MitoTam are currently underway. KKCG estimates that investments in the first two rounds of testing will amount to six million dollars
Springtide Ventures holds half ownership of a MitoTam and Senescence patents